| 1 |
34069967 | Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents. | 2021 May 18 |
1 |
| 2 |
28543772 | PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. | 2017 Sep |
5 |
| 3 |
27530326 | CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. | 2016 Oct 15 |
1 |
| 4 |
26438157 | Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. | 2015 Dec |
2 |
| 5 |
24216281 | Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. | 2014 Jan |
2 |
| 6 |
24556618 | Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. | 2014 Apr 15 |
3 |
| 7 |
21926192 | The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice. | 2011 Dec |
1 |